• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[Treatment and prevention of cognitive dysfunction in patients with arterial hypertension and atherosclerosis: results of a randomized double-blind placebo-controlled trial of cerebrolysin].

作者信息

Vereshchagin N V, Suslina Z A, Timerbaeva S L, Kashina E M, Gnezditskiĭ V V, Maksimova M Iu, Rebrova O Iu, Smirnova I N

出版信息

Ter Arkh. 2001;73(4):22-7.

PMID:11494441
Abstract

AIM

To assess therapeutic and prophylactic effect of large-dose cerebrolysin (15 ml/day for 28 days) in hypertensive and atherosclerotic patients with cognitive disorders.

MATERIAL AND METHODS

Cerebrolysin was given annually (15 ml/day for 28 days) for 2 years to 42 patients in a randomized double-blind placebo-controlled study. The effect was stated by clinical status, neuropsychological and neurophysiological data.

RESULTS

In mild disturbances of cognitive functions in patients with arterial hypertension and atherosclerosis courses of cerebrolysin with one-year interval produce stable improvement of subjective status, productivity of memory, attention and thinking which persist for at least a year after the course. The clinical data agree with positive trend in neurophysiological parameters of cognitive component of the response of evoked potentials P-300.

CONCLUSION

A course of 28-day annual treatment with cerebrolysin (15 ml/day) of patients with mild defects of cognitive functions stabilizes the process, leads to regression of cognitive disorders predicting vascular dementia.

摘要

相似文献

1
[Treatment and prevention of cognitive dysfunction in patients with arterial hypertension and atherosclerosis: results of a randomized double-blind placebo-controlled trial of cerebrolysin].
Ter Arkh. 2001;73(4):22-7.
2
Cerebrolysin enhances cognitive recovery of mild traumatic brain injury patients: double-blind, placebo-controlled, randomized study.脑活素可促进轻度创伤性脑损伤患者的认知恢复:双盲、安慰剂对照、随机研究。
Br J Neurosurg. 2013 Dec;27(6):803-7. doi: 10.3109/02688697.2013.793287. Epub 2013 May 8.
3
Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial.脑活素治疗血管性痴呆的随机、双盲、安慰剂对照多中心临床试验:临床转归的改善。
J Stroke Cerebrovasc Dis. 2011 Jul-Aug;20(4):310-8. doi: 10.1016/j.jstrokecerebrovasdis.2010.01.012. Epub 2010 Jul 24.
4
[Neuropsychological evaluation of long-term therapy of Alzheimer's disease using different cerebrolysin dosages].[使用不同剂量脑蛋白水解物对阿尔茨海默病进行长期治疗的神经心理学评估]
Zh Nevrol Psikhiatr Im S S Korsakova. 2005;105(1):52-5.
5
Clinical experience with Cerebrolysin.脑蛋白水解物的临床经验。
J Neural Transm Suppl. 2000;59:293-300.
6
[Cerebrolysin treatment of mild cognitive impairment of vascular genesis].[脑蛋白水解物治疗血管生成相关轻度认知障碍]
Ter Arkh. 2007;79(6):65-9.
7
[A randomized, double-blind, placebo-controlled study of Cerebrolysin safety and efficacy in the treatment of acute ischemic stroke].脑活素治疗急性缺血性卒中安全性和有效性的随机、双盲、安慰剂对照研究
Zh Nevrol Psikhiatr Im S S Korsakova. 2004(Suppl 11):51-5.
8
[4th International Symposium. "Cerebrolysin: pharmacological effects and role in clinical practice"].[第四届国际研讨会。“脑蛋白水解物:药理作用及在临床实践中的作用”]
Zh Nevrol Psikhiatr Im S S Korsakova. 2002;102(9):69-70.
9
[The effect of cerebrolysin on moderate cognitive impairment in cerebral vascular insufficiency (a clinical and electrophysiological study)].
Zh Nevrol Psikhiatr Im S S Korsakova. 2007;107(5):32-8.
10
[An effect of long-term cerebrolysin therapy in combination with neuroleptics on behavioral and cognitive disturbances in endogenous childhood autism].[长期脑蛋白水解物联合抗精神病药物治疗对儿童内源性孤独症行为和认知障碍的影响]
Zh Nevrol Psikhiatr Im S S Korsakova. 2006;106(2):21-5.

引用本文的文献

1
Cerebrolysin for vascular dementia.脑蛋白水解物用于治疗血管性痴呆。
Cochrane Database Syst Rev. 2019 Nov 11;2019(11):CD008900. doi: 10.1002/14651858.CD008900.pub3.